vyluma-logo-final.jpg
Vyluma Meets with FDA on Atropine Sulfate Ophthalmic Solution 0.01% Under Development to Treat Pediatric Myopia
June 18, 2024 07:30 ET | Vyluma, Inc.
Vyluma Discusses Response to FDA’s Questions and Clarifies Regulatory Pathway for its 505(b)(2) NDA, NVK002 to slow the progression of myopia in children.
vyluma-logo-final.jpg
Vyluma Announces Marketing Authorization Application Validation for the European Union
May 29, 2024 07:30 ET | Vyluma, Inc.
Vyluma announces Marketing Authorisation Application (MAA) validation for the EU for NVK002 to slow the progression of pediatric myopia.
vyluma-logo-final.jpg
Vyluma Announces Positive Results From Second Stage of Phase III CHAMP Study of NVK002 for the Treatment of Myopia in Children
October 11, 2023 07:00 ET | Vyluma, Inc.
BRIDGEWATER, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today positive...
vyluma-logo-final.jpg
Vyluma Announces FDA Acceptance of New Drug Application for NVK002, Its Novel Investigational Treatment for Pediatric Myopia
June 06, 2023 07:00 ET | Vyluma, Inc.
BRIDGEWATER, N.J., June 06, 2023 (GLOBE NEWSWIRE) -- June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced...
vyluma-logo-final.jpg
Vyluma to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023 07:00 ET | Vyluma, Inc.
BRIDGEWATER, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it...
vyluma-logo-final.jpg
Vyluma Announces Positive Results From Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children
October 27, 2022 12:00 ET | Vyluma, Inc.
BRIDGEWATER, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced top-line...
vyluma-logo-final.jpg
Vyluma Completes Last Patient Visit for Primary Analysis of Pivotal Phase III CHAMP Study Evaluating NVK002 for the Treatment of Myopia Progression in Children
September 01, 2022 07:00 ET | Vyluma, Inc.
BRIDGEWATER, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the...